Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies

被引：0
|
作者：
Ronald Goldwater
Azra Hussaini
Bill Bosch
Paul Nemeth
机构：
[1] PAREXEL Early Phase Clinical Unit,
[2] Churchill Pharmaceuticals LLC,undefined
来源：
Clinical Pharmacokinetics | 2017年 / 56卷
关键词：
Meloxicam; Abiraterone; Healthy Male Subject; Abiraterone Acetate; Dose Proportionality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：803 / 813
页数：10
相关论文
共 50 条
  • [1] Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies
    Goldwater, Ronald
    Hussaini, Azra
    Bosch, Bill
    Nemeth, Paul
    CLINICAL PHARMACOKINETICS, 2017, 56 (07) : 803 - 813
  • [2] Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects
    Jordan, Tamas
    Basa-Denes, Orsolya
    Angi, Reka
    Orosz, Janos
    Otvos, Zsolt
    Ujhelyi, Andrea
    Filipcsei, Genoveva
    Molnar, Laszlo
    Solymosi, Tamas
    Glavinas, Hristos
    Capone, Dominic
    Whitfield, Nicola
    McDermott, John
    McKenzie, Litza
    Shurety, Lauren
    Duus, Elizabeth Manning
    PHARMACEUTICS, 2021, 13 (12)
  • [3] Single-dose, four-way crossover, open-label, relative bioavailability (BA) studies of a novel formulation of abiraterone acetate (AA) versus the reference formulation under fasted conditions in healthy male subjects.
    Goldwater, Ronald
    Hussaini, Azra
    Zhang, Yuxin
    Bosch, Bill
    Nemeth, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets
    Feng, Zeying
    Liu, Yaxin
    Kuang, Yun
    Yang, Shuang
    Li, Jinlei
    Ye, Ling
    Huang, Jie
    Pei, Qi
    Huang, Yuanyuan
    Yang, Guoping
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 3 - 12
  • [5] Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: A randomized, open-label, two-period, comparative crossover study
    Park, JY
    Kim, KA
    Park, PW
    Suh, KH
    Lee, GS
    CLINICAL THERAPEUTICS, 2004, 26 (12) : 2092 - 2101
  • [6] Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: A randomized, open-label, two-period, comparative, crossover study
    Park, Ji-Young
    Kim, Kyoung-Ah
    Park, Pil-Whan
    Lee, Ock-Je
    Ryu, Jong Hyeon
    Lee, Geun Hyeog
    Ha, Mun Choun
    Kim, Jin Sun
    Kang, Seoung Woo
    Lee, Kyung Ryul
    CLINICAL THERAPEUTICS, 2006, 28 (11) : 1837 - 1847
  • [7] Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
    Acharya, M.
    Bernard, A.
    Gonzalez, M.
    Jiao, J.
    De Vries, R.
    Tran, N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1583 - 1590
  • [8] Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
    M. Acharya
    A. Bernard
    M. Gonzalez
    J. Jiao
    R. De Vries
    N. Tran
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1583 - 1590
  • [9] Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects
    Park, JY
    Kim, KA
    Lee, GS
    Park, PW
    Kim, SL
    Lee, YS
    Lee, YW
    Shin, EK
    CLINICAL THERAPEUTICS, 2004, 26 (05) : 715 - 723
  • [10] Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation With a Film-Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study
    Roh, Hyerang
    Son, Hankil
    Lee, Donghwan
    Yeon, Kyu Jeong
    Kim, Hyun Soo
    Kim, Hohyun
    Park, Kyungsoo
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 205 - 214
12345